Nifty
Sensex
:
:
10397.45
33844.86
37.05 (0.36%)
141.27 (0.42%)

Pharmaceuticals & Drugs

Rating :
40/99

BSE: 532296 | NSE: GLENMARK

524.95
1.00 (0.19%)
21-Feb-2018 | 3:54PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 524.00
  • 528.00
  • 521.50
  • 523.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 559258
  • 2935.82
  • 957.95
  • 517.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,801.13
  • 17.71
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 18,468.42
  • 0.38%
  • 2.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.53%
  • 2.60%
  • 10.84%
  • FII
  • DII
  • Others
  • 2.78%
  • 2.54%
  • 34.71%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Net Sales
2,203.66
2,535.01
-13.07%
2,256.59
2,224.11
1.46%
2,363.00
1,943.05
21.61%
2,457.18
2,281.25
7.71%
Expenses
1,880.97
1,769.98
6.27%
1,868.19
1,775.34
5.23%
1,785.55
1,563.98
14.17%
2,013.34
1,978.62
1.75%
EBITDA
322.69
765.02
-57.82%
388.40
448.77
-13.45%
577.45
379.07
52.33%
443.84
302.63
46.66%
EBIDTM
14.64%
30.18%
17.21%
20.18%
24.44%
19.51%
18.06%
13.27%
Other Income
-23.16
14.57
-
29.73
-1.84
-
15.29
75.92
-79.86%
-51.29
11.69
-
Interest
70.47
61.74
14.14%
69.84
62.87
11.09%
70.86
43.04
64.64%
69.67
47.50
46.67%
Depreciation
75.38
62.53
20.55%
75.23
68.70
9.51%
77.73
64.23
21.02%
68.90
62.78
9.75%
PBT
153.67
655.33
-76.55%
273.05
315.36
-13.42%
444.14
347.71
27.73%
173.03
204.04
-15.20%
Tax
48.93
178.23
-72.55%
58.93
91.77
-35.79%
110.76
120.93
-8.41%
-10.73
32.75
-
PAT
104.74
477.10
-78.05%
214.12
223.58
-4.23%
333.38
226.78
47.01%
183.76
171.29
7.28%
PATM
4.75%
18.82%
9.49%
10.05%
14.11%
11.67%
7.48%
7.51%
EPS
3.71
16.91
-78.06%
7.59
7.92
-4.17%
11.81
8.04
46.89%
6.51
6.08
7.07%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
9,280.43
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
1,975.71
Net Sales Growth
3.31%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
5.61%
 
Cost Of Goods Sold
3,031.20
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
472.22
Gross Profit
6,249.23
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
1,503.48
GP Margin
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
76.10%
Total Expenditure
7,548.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
1,175.18
Power & Fuel Cost
-
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
19.48
% Of Sales
-
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
0.99%
Employee Cost
-
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
173.54
% Of Sales
-
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
8.78%
Manufacturing Exp.
-
1,044.48
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
154.22
% Of Sales
-
11.50%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
7.81%
General & Admin Exp.
-
525.16
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
175.40
% Of Sales
-
5.78%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
8.88%
Selling & Distn. Exp.
-
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
254.38
171.85
% Of Sales
-
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
8.70%
Miscellaneous Exp.
-
88.52
38.82
38.48
228.40
33.61
0.00
0.00
33.15
6.79
171.85
% Of Sales
-
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
0.43%
EBITDA
1,732.38
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
800.53
EBITDA Margin
18.67%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
40.52%
Other Income
-29.43
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
53.69
Interest
280.84
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
71.04
Depreciation
297.24
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
102.68
71.68
PBT
1,043.89
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
385.84
711.50
Tax
207.89
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
75.41
79.39
Tax Rate
19.91%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
11.16%
PAT
836.00
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
191.66
632.13
PAT before Minority Interest
835.97
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
193.47
632.11
Minority Interest
-0.03
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
0.02
PAT Margin
9.01%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
32.00%
PAT Growth
-23.91%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
-69.68%
 
Unadjusted EPS
29.62
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40
7.70
25.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
1,517.87
Share Capital
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
24.87
Total Reserves
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
1,493.00
Non-Current Liabilities
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
1,085.49
Secured Loans
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
196.13
Unsecured Loans
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
794.81
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
0.00
Current Liabilities
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
320.72
Trade Payables
1,903.52
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
230.79
Other Current Liabilities
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
72.17
Short Term Borrowings
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
0.00
Short Term Provisions
102.65
134.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
17.76
Total Liabilities
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
2,925.56
Net Block
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
918.51
Gross Block
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
1,124.10
Accumulated Depreciation
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
205.59
Non Current Assets
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
1,274.56
Capital Work in Progress
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
337.23
Non Current Investment
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
18.82
Long Term Loans & Adv.
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
0.00
Current Assets
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
1,651.00
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
400.74
Sundry Debtors
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
806.85
Cash & Bank
1,056.36
857.12
775.88
800.67
607.31
321.92
195.83
107.02
71.48
156.51
Other Current Assets
1,274.90
391.88
31.44
104.37
635.91
593.95
465.11
527.31
422.09
286.90
Short Term Loans & Adv.
775.74
594.89
742.94
768.44
540.03
518.90
322.39
527.31
422.09
286.90
Net Current Assets
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
1,330.28
Total Assets
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92
2,925.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
371.78
PBT
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
268.88
711.50
Adjustment
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
274.15
133.39
Changes in Working Capital
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
-384.56
Cash after chg. in Working capital
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
460.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
-88.55
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
-509.62
Net Fixed Assets
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
-188.35
Net Investments
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
-57.60
Others
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
-263.67
Cash from Financing Activity
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
188.58
Net Cash Inflow / Outflow
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
50.75
Opening Cash & Equivalents
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
105.75
Closing Cash & Equivalent
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48
156.51

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
63.79
61.03
ROA
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
26.01%
ROE
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
57.35%
ROCE
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
37.88%
Fixed Asset Turnover
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
1.43
2.19
Receivable days
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
151.98
124.70
Inventory Days
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
88.92
60.90
Payable days
98.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
62.10
61.26
Cash Conversion Cycle
72.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
178.80
124.34
Total Debt/Equity
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
1.31
0.65
Interest Cover
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32
2.85
11.02

News Update:


  • Glenmark Pharmaceuticals presents new data on GBR 830
    19th Feb 2018, 09:04 AM

    The GBR 830 Phase 2a study was a double-blind, placebo-controlled study in adults with moderate-to-severe AD

    Read More
  • Glenmark Pharmaceuticals recalls Mometasone Furoate Cream from US market
    9th Feb 2018, 09:05 AM

    Mometasone Furoate Cream is used to treat skin conditions such as eczema, psoriasis, allergies, and rash

    Read More
  • Glenmark Pharma - Quarterly Results
    8th Feb 2018, 15:56 PM

    Read More
  • Glenmark initiates Phase IIb dose range finding study for GRC 27864
    15th Jan 2018, 13:34 PM

    GRC 27864 is a potent, selective, and orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), a novel therapeutic target in pain management

    Read More
  • Glenmark Pharmaceutical launches biosimilar of Adalimumab in India
    4th Jan 2018, 14:01 PM

    The biosimilar will be marketed by Glenmark under the brand name ADALY

    Read More
  • Glenmark receives ANDA approval for Norethindrone Acetate, Ethinyl Estradiol Tablets
    27th Dec 2017, 09:14 AM

    According to IQVIA sales data for the 12 month period ending October 2017, the Minastrin 24 Fe Tablets market achieved annual sales of approximately $337.0 million

    Read More
  • Glenmark Pharma reports successful trial for Nasal Spray
    14th Dec 2017, 10:29 AM

    The company is planning to submit its first NDA to the USFDA for Ryaltris for the treatment of patients with SAR in the first quarter of CY 2018

    Read More
  • Glenmark starts trial of Investigational Immuno-Oncology Agent GBR 1342
    8th Dec 2017, 10:36 AM

    GBR 1342 simultaneously targets CD38, as well as the CD3 T cell co-receptor

    Read More
  • Glenmark closes DCP for generic Seretide Accuhaler in Nordic region
    1st Dec 2017, 09:14 AM

    This will be Glenmark’s first Inhaled respiratory product approval in Europe

    Read More
  • USFDA issues seven observations to Glenmark Pharmaceuticals’ Baddi unit
    28th Nov 2017, 10:21 AM

    The Baddi unit currently contributes approximately 10 percent of the revenue of US sales

    Read More
  • Glenmark receives final approval for generic Loestrin Fe 1/20 Tablets
    22nd Nov 2017, 11:07 AM

    The Loestrin Fe 1/20 Tablets market achieved annual sales of approximately $116.8 million

    Read More
  • Glenmark receives final approval for generic Loestrin 24 Fe Tablets
    20th Nov 2017, 09:06 AM

    The Loestrin 24 Fe Tablets market achieved annual sales of approximately $96.7 million for 12 month period ending September 2017

    Read More
  • Glenmark Pharmaceuticals launches nicotine replacement therapy product ‘Kwitz’
    16th Nov 2017, 15:19 PM

    Kwitz nicotine gum will be available in two variants of 2 mg as an OTC product and 4mg as prescription product

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.